These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 18003803)

  • 1. Evaluation of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.
    Sakoulas G; Rose W; Rybak MJ; Pillai S; Alder J; Moellering RC; Eliopoulos GM
    J Clin Microbiol; 2008 Jan; 46(1):220-4. PubMed ID: 18003803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Rose WE; Leonard SN; Rybak MJ
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3061-7. PubMed ID: 18591272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence of a clinical daptomycin-resistant Staphylococcus aureus isolate during treatment of methicillin-resistant Staphylococcus aureus bacteremia and osteomyelitis.
    Marty FM; Yeh WW; Wennersten CB; Venkataraman L; Albano E; Alyea EP; Gold HS; Baden LR; Pillai SK
    J Clin Microbiol; 2006 Feb; 44(2):595-7. PubMed ID: 16455920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Rose WE; Leonard SN; Sakoulas G; Kaatz GW; Zervos MJ; Sheth A; Carpenter CF; Rybak MJ
    Antimicrob Agents Chemother; 2008 Mar; 52(3):831-6. PubMed ID: 17999971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical rationale for treatment of endocarditis caused by methicillin-susceptible Staphylococcus aureus developing nonsusceptibility to daptomycin.
    Gqada Z; Marais B; Wasserman E; Bamford C; Orth H; Sakoulas G; Rose W; Rybak MJ; Pillai S; Alder J; Moellering RC; Eliopoulos GM
    J Clin Microbiol; 2008 Jul; 46(7):2471; author reply 2471-2. PubMed ID: 18614667
    [No Abstract]   [Full Text] [Related]  

  • 6. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Telavancin in therapy of experimental aortic valve endocarditis in rabbits due to daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus.
    Xiong YQ; Hady WA; Bayer AS; Chen L; Kreiswirth BN; Yang SJ
    Antimicrob Agents Chemother; 2012 Nov; 56(11):5528-33. PubMed ID: 22890759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis.
    Julian K; Kosowska-Shick K; Whitener C; Roos M; Labischinski H; Rubio A; Parent L; Ednie L; Koeth L; Bogdanovich T; Appelbaum PC
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3445-8. PubMed ID: 17620372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis.
    Lemaire S; Kosowska-Shick K; Julian K; Tulkens PM; Van Bambeke F; Appelbaum PC
    Clin Microbiol Infect; 2008 Aug; 14(8):766-77. PubMed ID: 18727801
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced expression of dltABCD is associated with the development of daptomycin nonsusceptibility in a clinical endocarditis isolate of Staphylococcus aureus.
    Yang SJ; Kreiswirth BN; Sakoulas G; Yeaman MR; Xiong YQ; Sawa A; Bayer AS
    J Infect Dis; 2009 Dec; 200(12):1916-20. PubMed ID: 19919306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
    Tsuji BT; Rybak MJ
    Antimicrob Agents Chemother; 2005 Jul; 49(7):2735-45. PubMed ID: 15980344
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microbiological and genotypic analysis of methicillin-resistant Staphylococcus aureus bacteremia.
    McCalla C; Smyth DS; Robinson DA; Steenbergen J; Luperchio SA; Moise PA; Fowler VG; Sakoulas G
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3441-3. PubMed ID: 18606839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies.
    Rose WE; Rybak MJ; Kaatz GW
    J Antimicrob Chemother; 2007 Aug; 60(2):334-40. PubMed ID: 17540670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daptomycin non-susceptible, vancomycin-intermediate Staphylococcus aureus endocarditis treated with ceftaroline and daptomycin: case report and brief review of the literature.
    Baxi SM; Chan D; Jain V
    Infection; 2015 Dec; 43(6):751-4. PubMed ID: 25805524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA).
    Shafiq I; Bulman ZP; Spitznogle SL; Osorio JE; Reilly IS; Lesse AJ; Parameswaran GI; Mergenhagen KA; Tsuji BT
    Infect Dis (Lond); 2017 May; 49(5):410-416. PubMed ID: 28116950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of daptomycin in experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
    Sakoulas G; Eliopoulos GM; Alder J; Eliopoulos CT
    Antimicrob Agents Chemother; 2003 May; 47(5):1714-8. PubMed ID: 12709345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
    Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
    N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006.
    Holmes RL; Jorgensen JH
    Antimicrob Agents Chemother; 2008 Feb; 52(2):757-60. PubMed ID: 18039923
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.
    Rose WE; Schulz LT; Andes D; Striker R; Berti AD; Hutson PR; Shukla SK
    Antimicrob Agents Chemother; 2012 Oct; 56(10):5296-302. PubMed ID: 22869564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.